Track market-moving stories before they get noisy

Key Takeaways ACHC raised full-year Adjusted EBITDA guidance after Q1 2026 revenues rose 7.6% to $828.8 million.ACHC is prioritizing returns from existing assets and plans 2026 capital spending of $255-$280 million.ACHC is resolving disputes, strengthening compliance, and improving retention. Acadia Healthcare Company, Inc. (ACHC - Free Report) demonstrates how a mission-driven healthcare company can create long-term shareholder value. As the largest standalone behavioral health provider in the United States, operating 275 facilities and more than 12,400 beds across 40 states, Acadia plays a critical role in addressing the nation's growing mental health and addiction treatment needs. Following a challenging period marked by regulatory scrutiny and industry-wide pressures, it has focused on rebuilding operational strength and restoring investor confidence.

Over the past year, management has taken meaningful steps to protect shareholder value. Acadia resolved some legacy billing disputes, worked toward strengthening compliance standards and improving workforce retention, and brought back experienced industry leader Debbie Osteen as CEO. These actions signal a commitment to accountability, operational discipline and long-term value creation.

Acadia's strategy has also evolved. Rather than pursuing growth, it has shifted toward maximizing returns from its existing footprint, limiting planned 2026 capital expenditures to a range of $255 million to $280 million. This strategic shift is evident in the company’s recent results, with first-quarter 2026 revenues rising 7.6% year over year to $828.8 million and management raising its full-year adjusted EBITDA guidance from $575-$610 million to $580-$615 million.

Demand for mental health and addiction treatment continues to rise, supported by growing awareness and significant unmet patient needs. While some historical expansions weighed on returns, many recently developed facilities are approaching maturity. Acadia now has an opportunity to convert years of investment into improved profitability, creating a potential turnaround opportunity for long-term investors.

How Are Competitors Faring?Peers such as Universal Health Services, Inc. (UHS - Free Report) and LifeStance Health Group, Inc. (LFST - Free Report) are also pursuing growth and operational efficiency initiatives.

Universal Health Services is increasingly focused on extracting greater value from its behavioral health network. Alongside efforts to improve occupancy and outpatient growth, UHS recently announced its $835 million acquisition of Talkspace to expand patient access and broaden treatment options.

LifeStance Health continues to strengthen its outpatient mental health platform through clinician expansion and technology-enabled care, reflecting LFST’s efforts to capture a bigger share of the growing demand for behavioral health services.

ACHC’s Price Performance, Valuation & EstimatesShares of Acadia have gained 20.9% over the past year compared to the industry’s 8.4% decline over the same period.

Image Source: Zacks Investment Research

From a valuation standpoint, ACHC trades at a forward price-to-earnings ratio of 15.71X, up from the industry average of 8.45X.  ACHC carries a Value Score of C.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for ACHC’s 2026 earnings is pegged at $1.50 per share, which has moved 1 cent up in the past 60 days.

Image Source: Zacks Investment Research

Acadia currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

-

Native AI agents added to RingCX workflows giving businesses automated outreach, intelligent handoffs, and more

LAS VEGAS--(BUSINESS WIRE)--RingCentral, Inc. (NYSE: RNG) today announced the expansion of AIR Pro™ to deliver agentic AI capabilities across the RingCentral customer engagement portfolio. The expansion includes new capabilities within RingCX™ that help businesses with end-to-end customer resolution, automated outreach, and intelligent hand-offs. These enhancements also strengthen how customer context is captured and carried within RingCX. When a conversation transfers to a live agent, that agent has a more complete picture, including prior interactions, data from connected systems via APIs, and relevant recordings — without having to ask the customer to repeat themselves. The context layer continuously informs itself, getting smarter with every interaction.

“RingCentral offers the broadest range of customer engagement solutions that address both informal and formal contact center requirements. Our announcement today is about expanding AIR Pro and adding key updates to RingCX as we make progress toward our vision of AI agents and humans working together,” said Jim Dvorkin, SVP of Customer Experience Products at RingCentral. “Our innovations for RingCX continue to be well received by our customers. The addition of native AI agents, along with autonomous outreach, intelligent handoffs, and our AI powered workflow builder for RingCX helps businesses improve customer experiences and achieve measurable results.”

Where Humans and AI Agents Work Together

Highlighted at Customer Contact Week (CCW) Las Vegas 2026, RingCentral rolled out the following updates:

Native AI Agents: Embedded directly into RingCX workflows, native AI agents help with inbound and outbound interactions across voice and digital channels. For example, a business can run multi-step workflows from start to finish, such as confirm an appointment, handle verification, and update a record all within a single call. Autonomous Outreach: Leverage AI agents to proactively initiate conversation outreach triggered by real-time events: appointment reminders, payment notifications, service updates. For example, a credit card payment is missed. AIR Pro calls the customer, confirms the outstanding balance, offers payment options, and processes the payment over the phone. Intelligent Handoffs: When a conversation requires human judgment or empathy, AI agents in RingCX can transfer seamlessly to live agents, carrying full customer history and CRM data so the conversation continues without interruption, repetition, or lost context. AI-powered Workflow Builder: A natural language interface for building RingCX workflows on-demand, customers are able to prompt commands through RingCX’s AI Virtual Assistant (AVA) describing what they need, and it creates a workflow automatically — no coding, no technical resources required. AI-powered RingCX Analytics: Enables business and contact center leaders to prompt questions through RingCentral’s AI Virtual Assistant (AVA) within the RingCX interface to retrieve answers and specific metrics. For example, a newly hired supervisor can ask, "What report should I use to see an agent’s attendance and performance?" and AVA surfaces the answer instantly. New WEM Capabilities

RingCentral’s native WEM solution, called RingWEM, brings together AI Quality Management, AI Interaction Analytics, and AI Workforce Management embedded directly into RingCX – helping businesses reduce average call handle times, and improve customer satisfaction without a fragmented toolset that has long held back contact center performance. New RingWEM capabilities include:

RingWEM with Live Screen Monitoring: This gives supervisors visibility into how agents handle customer interactions, with the ability to whisper, coach, or step in without disrupting the customer experience. For example, it gives supervisors visibility during the call, seeing the agent’s screen in real time, and watching how agents address a problem, while giving coaching suggestions when the conversation is still live. Added Digital Channels

RingCX supports more than 20 digital channels, along with inbound and outbound voice allowing agents to manage various customer interactions from a single, unified interface. RingCX goes beyond the standard support for WhatsApp Messaging, and now includes WhatsApp Voice support.

WhatsApp Voice Support: With WhatsApp Voice in RingCX, customers can move from a messaging conversation to voice without leaving WhatsApp. The agent picks up the call with a complete view of the customer journey, including a summary of each interaction. “As a RingCX and AIR Pro customer, we're expanding our use of AI to drive a consistent customer experience while also enabling more automated AI and human interactions,” said Jaimie Bell, VP of Client Solutions at Office Gurus. “The expansion of AI Agents in RingCX, powered by AIR Pro, is really exciting. We're looking forward to it giving us more control and visibility into deploying AI agents at scale without sacrificing the quality our customers expect. We're early in implementation, and already seeing how AI agents will help us move faster, reduce manual overhead, and deliver a more seamless customer experience.”

RingCX Momentum

As of the end of Q1 2026, more than 1,700 businesses have adopted RingCX, up over 70% year-over-year – with more than half of them utilizing AI.

RingCX customers are achieving measurable results across industries. For example, in healthcare, Sun River Health achieved a 95% first-call resolution rate — 25% above industry standard. In entertainment, The Escape Game reduced costs by 50% while increasing bookings by 7%, and the San Diego Symphony cut box office hold times by 95%.

“The industry is moving beyond AI assistants towards increasingly autonomous AI agents that can participate in customer journeys alongside human workers,” said Hayley Sutherland, Conversational AI Analyst at IDC. “Organizations will need a common framework for managing performance, quality, analytics, and governance across both — and having that native to the contact center platform is the right approach. RingCentral's direction reflects its commitment to both supporting its customers with the capabilities needed today, and taking them where the market is headed.”

Pricing & Availability

Native AI Agents in RingCX and Automated Outreach will be available on a consumption basis, aligned with AIR Pro pricing. RingWEM with Live Screen Monitoring — will be priced on a seat basis or included in the RingCX Ultimate tier. New RingCX capabilities are currently in beta with general availability in 2H 2026. AI-powered RingCX Analytics and RingWEM with Live Screen Monitoring will be available in Q3.

For additional details or demo requests, visit the RingCentral booth #411 at CCW Las Vegas, or click here.

Join the RingCentral “CCW Special Edition” of AI Real Talk—Live or on-demand Elevate Every Customer Experience: Keeping Humans in the Loop While Scaling AI June 23 | 10:00 AM PT / 1:00 PM ET

About RingCentral

RingCentral is a global leader in AI–powered customer engagement, delivering an integrated platform for business phone, SMS, contact center, workforce engagement management, video collaboration, and messaging. Powered by advanced AI capabilities, RingCentral delivers intelligence at every phase of the conversation journey — before, during, and after each human interaction. With RingCentral, businesses can work smarter, respond faster, and connect more meaningfully with their customers. Visit ringcentral.com to learn more.

©2026 RingCentral, Inc. All rights reserved. RingCentral, RingCX, RingCentral AIR Pro, and the RingCentral logo are trademarks of RingCentral, Inc.

More News From RingCentral, Inc.

Back to Newsroom

Industrial might is back in vogue, and not just for space-industry stocks. A new form of transportation is soon to make its debut in cities around the globe: electric vertical takeoff and landing (eVTOL) vehicles. Joby Aviation (JOBY 3.04%) is one of the publicly traded companies that manufactures these innovative aircraft, and it believes that it can transform transportation across cities.

Its product is neither an airplane nor a helicopter, but something in between, and fully electric-powered. With its stock price currently at just $9 per share, could getting in early on eVTOL pioneer Joby Aviation help make you rich? Let's take a closer look and find out.

Today's Change

(

-3.04

%) $

-0.29

Current Price

$

9.26

The future of short-haul flights The idea for eVTOLs came from two sources: the plague of car traffic in most large cities, and noise pollution from helicopters, which prevents them from operating in many areas. An eVTOL can operate quietly compared to a helicopter, transporting small groups of passengers from point to point using "vertiports" across metro areas.

Joby's aircraft is currently in the middle of certification with the Federal Aviation Administration (FAA), which requires rigorous testing for all eVTOL start-ups due to the novel nature of the vehicles. Joby began testing in 2018 and is reportedly close to the finish line, aiming to secure full regulatory approval in both the United States and Dubai within the next 12 months.

The company currently generates just a sliver of revenue from its Blade business, which is a helicopter and private-flight rideshare network focused on New York City. In the future, Joby plans to operate its own eVTOL ride-sharing for customers. Instead of just selling commercial aircraft to operators like Boeing, Joby wants to keep its aircraft and sell tickets directly to users through its own vertiport network. It will do so with partners like Delta Air Lines, connecting people at the airport to the potential of eVTOL services, a prime customer use case.

Image source: Getty Images.

Manufacturing progress and cash burn To get ahead of anticipated FAA approval, Joby has begun increasing its manufacturing capacity. It is currently producing two eVTOLs a month, for a rate of 24 per year. In the near future, it wants to double this manufacturing pace, and eventually produce 500 vehicles per year. With hundreds of cities around the world that could utilize eVTOL taxi networks, there is theoretical demand for this level of output from Joby and other eVTOL manufacturers racing for FAA approval.

Up-front spending will be massive. Joby needs to build aircraft and secure leases for vertiports before selling tickets to customers, which is why free cash flow has worsened over the past few years, hitting a record burn of $660 million over the last 12 months. At the end of the first quarter, the company had $2.5 billion in cash and equivalents, which gives it a few years of breathing room, but it's still not on a firm financial footing.

JOBY Revenue (TTM) data by YCharts.

Can Joby stock deliver life-changing returns? Joby Aviation is a high-risk stock. Let's say the company can eventually manufacture hundreds of aircraft a year, operate many air taxi networks in cities across the United States and globally, and improve traffic levels. If so, it's likely to get hundreds of millions (if not billions) of dollars in annual ticket revenue from customers who will pay a pretty penny to fly over traffic to places like the nearest airport.

The problem is that, despite a low per-share price of $9, Joby Aviation's market value is still quite high for a company that is close to a pre-revenue start-up. It currently has a market cap of $9.2 billion, pricing in a lot of this theoretical success before any FAA approval has been made. That should make you think twice about whether the stock can deliver life-changing returns for your portfolio.

Despite making headway on its regulatory path, Joby Aviation (JOBY 3.04%) has spent much of 2026 flying into strong headwinds. Indeed, shares of the electric vertical takeoff and landing (eVTOL) stock have fallen about 30% on the year and trade far below their 52-week high of about $21.

What gives? Wall Street's patience, I suppose. Joby has not fundamentally changed in the last year. In fact, its prospects have only gotten better: The company has never been closer to achieving FAA certification, and it just successfully piloted an eVTOL in and around New York City.

If Joby stays on its current path, this 30% dip could, in retrospect, represent an attractive buying window. Let's take a look.

Today's Change

(

-3.04

%) $

-0.29

Current Price

$

9.26

Joby is the front-runner of the nascent eVTOL industry Imagine a large drone you and a few friends can ride in; it takes off straight up from the ground, flies across the city over traffic and congested streets, then lands near an airport or your office. That, in a nutshell, is the kind of air taxi service Joby Aviation is trying to create.

And it's not alone. Early on, Toyota became its manufacturing mentor and an early investor. Joby has also partnered with Delta Air Lines and Uber, and it made a strategic acquisition of Blade Air Mobility.

Image source: Joby Aviation.

Each of these partnerships can accelerate the rate at which it brings its air taxis to the market. So can the eIPP (eVTOL Integration Pilot Program), a White House-backed initiative to begin testing eVTOL operations in select cities ahead of FAA type certification. The program, slated to begin in the second half of this year, gives Joby a chance to build experience before commercialization begins.

Joby is currently in Stage 4 of the FAA's five-stage type certification process, and it began for-credit flight testing in March 2026. At this point, the FAA is scrutinizing Joby's aircraft to determine whether it meets requirements, rather than just reviewing a design on paper.

Nobody knows when this process will finish -- it could drag on for months -- but if this were a race among eVTOL companies, Joby would be in the lead. The closest competitor, Archer Aviation, recently began its own for-credit flight testing. Both companies are expected to start generating more substantial revenue within the next two years, as shown in the chart.

Data by YCharts

In 2021, Morgan Stanley published a report on eVTOLs and urban air mobility. In that report, it predicted, in the most bullish scenario, that the industry would grow to $1 trillion by 2040 and $9 trillion by 2050. As the researchers put it, "Our key message to investors: Temper your excitement with patience. The market opportunity for eVTOL/UAM could be far bigger than you think, but we believe it may require decades to reach high-volume commercialization.

Those interested in Joby today should approach the stock with the long-term perspective of decades, not years. For investors willing to wait that long, today's share price may ultimately matter far less than whether Joby turns a radical idea into a new mode of transportation.

Archer Aviation (ACHR 2.67%) and Kraken Robotics are two companies operating at the forefront of new technologies. Archer is a leader in electric vertical take-off and landing (eVTOL) aircraft, and Kraken is a leader in subsea batteries, ocean-floor mapping technologies, Lidar, and mine detection. Both companies have substantial growth opportunities in the defense sector.

Military budgets are rising around the world, and countries are taking steps to ensure that they are sufficiently positioned when it comes to next-gen defense technologies. With that in mind, is Archer Aviation or Kraken Robotics the better defense stock buy?

Image source: Getty Images.

Archer Aviation and Kraken Robotics at a glance Archer Aviation's business didn't post any sales last year, but the company did record revenue of $1.6 million in this year's first quarter and expects to begin commercial flight operations this year. The company currently has a market capitalization of roughly $4.2 billion.

Today's Change

(

-2.67

%) $

-0.14

Current Price

$

5.11

In addition to defense applications, Archer is also positioning commercial flights as a central component of its growth story. The company expects to begin commercial flights of its Midnight eVTOL aircraft in the United Arab Emirates this year, and it's moving through the certification process to secure the approval to fly in U.S. skies and other markets.

Meanwhile, Kraken recorded sales of roughly 102 million Canadian dollars (about $72 million USD based on the current exchange rate) in 2025. Kraken recorded net income of CA$2.9 million (roughly $2.1 million) last year, and Archer Aviation posted a net loss of $618.2 million.

Today's Change

(

-1.38

%) $

-0.07

Current Price

$

4.95

The scope of Kraken's business is also poised to expand dramatically thanks to the company's acquisition of Covelya -- another leader in the maritime technologies space. Kraken currently has a market cap of roughly $1.7 billion, but that figure will likely rise closer to $2 billion when the company issues new stock to complete its acquisition of Covelya.

Notably, both Archer and Kraken have partnerships with Anduril -- one of the most exciting companies when it comes to next-generation defense tech. Archer has teamed with Anduril to develop hybrid VTOL aircraft for military applications. Meanwhile, Kraken's batteries and sensor technologies are used in Anduril's GhostShark, Dive-LD, and Dive-XL unmanned, underwater drones. Covelya's Sonardyne technologies are also used in Anduril's sea drones, and the combination with Kraken should open up cross-selling opportunities across their respective customer bases and open the door for new selling and administrative efficiencies.

Which stock is the better buy? Between the two companies, I think Kraken stands out as the better buy right now. Despite having a significantly lower market capitalization, Kraken's commercialization ramp is significantly further along -- while also still offering big long-term growth potential. With Anduril seemingly set to ramp up production of its underwater drone platforms in the coming years, Kraken has some powerful performance catalysts on the horizon.

The company is also posting gross margins that look quite encouraging for a heavily hardware-focused business. The subsea tech specialist recorded a gross margin of 62.1% last year, and it's guiding for a gross margin between 55% and 60% this year.

Archer Aviation's business could scale rapidly, but I see a longer and tougher path to profitability and strong earnings growth. With that in mind, I think that Kraken stands out as a better buy for investors seeking next-gen defense plays.

ACHR advances VTOL testing and regulatory milestones, with the upcoming eIPP participation and Restricted Type Certificate program supporting intermediate-term US/UAE commercialization. With a growing order book nearing $6B as of 2024 and an expanded manufacturing cadence, the VTOL company appears well on track to rapidly monetize their offerings upon FAA certification. These tailwinds are, albeit, negated by ACHR's elevated cash burn rate as they intensify their multi-pronged testing/manufacturing/training/operations at Hawthorne Airport in LA/commercialization cadence.

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of PennyMac Financial Services, Inc. (NYSE: PFSI) resulting from allegations that PennyMac may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased PennyMac securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=51887 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

WHAT IS THIS ABOUT: On January 29, 2026, PennyMac filed a Current Report with the Securities and Exchange Commission on Form 8-K announcing PennyMac’s fourth quarter and full-year 2025 financial results. The report stated that PennyMac’s “servicing segment pretax income was $37.3 million, down from $157.4 million in the prior quarter and $87.3 million in the fourth quarter of 2024,” as well as “[retax income excluding valuation-related items was $47.8 million, down 70 percent from the prior quarter driven primarily by increased realization of mortgage servicing rights (MSR) cash flows as lower mortgage rates drove higher prepayment activity.”

On this news, PennyMac’s stock price fell $49.78 per share, or 33.3%, to close at $99.92 per share on January 30, 2026.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Attracting over 15.7 million MICE visits since 2007
Elevating Macao's international competitiveness through long-term
non-gaming investment

, /PRNewswire/ -- Since the opening of Sands® Macao in 2004, Sands China Ltd. has remained committed to contributing to Macao's development into a World Centre of Tourism and Leisure. As a trailblazer of Macao's integrated resort model, Sands China has placed hospitality, retail, entertainment, and MICE (meetings, incentives, conferences and exhibitions) at the core of its non-gaming development strategy. For over two decades, the company has continuously invested in both infrastructure and software to broaden the scope and depth of the city's industries, in support of the Macao SAR government's economic diversification direction.

Sands China has long played a proactive role in promoting Macao’s MICE industry, leveraging its world-class integrated resorts to enhance the city’s capacity and competitiveness in hosting large-scale international MICE events. As of now, Sands China has hosted nearly 12,800 MICE events, attracting over 15.7 million MICE visits from around the world. These efforts continue to strengthen Macao’s position as one of the premier MICE tourism destinations in Greater China, Asia, and globally. (The 2018 Macao International Environmental Co-operation Forum and Exhibition)

Sands China has long played a proactive role in promoting Macao’s MICE industry, leveraging its world-class integrated resorts to enhance the city’s capacity and competitiveness in hosting large-scale international MICE events. As of now, Sands China has hosted nearly 12,800 MICE events, attracting over 15.7 million MICE visits from around the world. These efforts continue to strengthen Macao’s position as one of the premier MICE tourism destinations in Greater China, Asia, and globally. (The 13th Macao International Travel (Industry) Expo, 2025)

Sands China has long played a proactive role in promoting Macao’s MICE industry, leveraging its world-class integrated resorts to enhance the city’s capacity and competitiveness in hosting large-scale international MICE events. As of now, Sands China has hosted nearly 12,800 MICE events, attracting over 15.7 million MICE visits from around the world. These efforts continue to strengthen Macao’s position as one of the premier MICE tourism destinations in Greater China, Asia, and globally. (The 14th Macao International Travel (Industry) Expo, 2026)

Sands China has long played a proactive role in promoting Macao’s MICE industry, leveraging its world-class integrated resorts to enhance the city’s capacity and competitiveness in hosting large-scale international MICE events. As of now, Sands China has hosted nearly 12,800 MICE events, attracting over 15.7 million MICE visits from around the world. These efforts continue to strengthen Macao’s position as one of the premier MICE tourism destinations in Greater China, Asia, and globally. (The 14th Macao International Travel (Industry) Expo, 2026)

Sands China has long played a proactive role in promoting Macao’s MICE industry, leveraging its world-class integrated resorts to enhance the city’s capacity and competitiveness in hosting large-scale international MICE events. As of now, Sands China has hosted nearly 12,800 MICE events, attracting over 15.7 million MICE visits from around the world. These efforts continue to strengthen Macao’s position as one of the premier MICE tourism destinations in Greater China, Asia, and globally. (Global Gaming Expo Asia 2026) With the opening of The Venetian® Macao in 2007, Sands China took a forward-looking approach by establishing Cotai Expo, the largest MICE facility in Macao — laying a solid foundation for the city's international competitiveness in the MICE industry. Over the years, the company has been steadfast in advancing non-gaming development, driving Macao's MICE sector to evolve from an emerging industry into a high-growth pillar. Sands China successfully developed and enriched the integrated model that enables multiple experiences within a single stop. To date, the company's total MICE facilities span over 1.6 million square feet, continuing to scale the international and professional development of the sector.

Under strong policy support from both the central and Macao SAR governments, Macao's MICE industry has expanded significantly, becoming one of the key engines driving progress in the city's diversification. Sands China has long played a proactive role in promoting the industry's advancement. It has leveraged its world-class integrated resorts to enhance Macao's capacity and competitiveness in hosting large-scale international MICE events, successfully attracting a wide range of globally influential, high-value conferences and exhibitions to the city.

As of now, Sands China has hosted nearly 12,800 MICE events across a broad spectrum of global industries, attracting over 15.7 million MICE visits from around the world. These efforts continue to strengthen Macao's position as one of the premier MICE tourism destinations in Greater China, Asia, and globally.

Sands China firmly believes that MICE serves as a powerful economic multiplier, conducive to fostering the development of related industries. Its strong international connectivity also enables the city to attract a broad base of global business travellers and professionals, further expanding Macao's international source markets. Sands China has long tapped into the continued hosting of high-quality international MICE events as part the company's approach to elevate Macao's appeal to global tourists. In 2025 alone, Sands China recorded 380,000 room nights by international guests across its integrated resorts.

Grant Chum, chief executive officer and executive director of Sands China Ltd., said: "Over the years, Sands China has played a pivotal role in developing Macao's MICE industry, integrating MICE deeply within our integrated resort model. We have built large-scale, high-quality MICE infrastructure in Macao, continuously elevating the sector into a strategic drawcard and tourism product that connects Macao with global markets, strengthens the city's international competitiveness, and supports its broader economic diversification. Since 2007, Sands China has attracted over 15.7 million MICE visits. As the local MICE industry continues to flourish, Macao has increasingly established itself as one of the world's most influential business and tourism destinations, underscoring the sector's contribution to the city's diversified economic growth.

"Looking ahead, Sands China will continue to align closely with the Macao SAR government's 'Tourism+' policy. Through the continued strengthening of synergies across non-gaming sectors, our company endeavours to further elevate Macao's global competitiveness and appeal, while supporting the development of its diversified economy, and remains committed to consolidating the city's position as a World Centre of Tourism and Leisure."

Sands China holds unwavering confidence in Macao's long term development trajectory. As the company continues to strengthen its business performance, it maintains its commitment to long-term investment in the city. The company is proactively deepening high-quality, non-gaming "Tourism+" initiatives to support Macao's overall development strategy –– striving to further enrich Macao's appeal as a City of Events and contribute to its long-term, sustainable and diversified growth.

About Sands China Ltd. 
Sands China Ltd. (Sands China or the Company) is incorporated in the Cayman Islands with limited liability and is listed on The Stock Exchange of Hong Kong Limited (HKEx: 1928). Sands China is the largest operator of integrated resorts in Macao. The Company's integrated resorts on the Cotai Strip comprise The Venetian® Macao, The Plaza® Macao, The Parisian® Macao and The Londoner® Macao. The Company also owns and operates Sands® Macao on the Macao peninsula. The Company's portfolio features a diversified mix of leisure and business attractions and transportation operations, including large meeting and convention facilities; a wide range of restaurants; shopping malls; world-class entertainment at The Venetian Arena, The Londoner Arena, The Venetian Theatre, The Parisian Theatre, The Londoner Theatre and Sands Theatre; and a high-speed Cotai Water Jet ferry service between Hong Kong and Macao. The Company's Cotai Strip portfolio has the goal of contributing to Macao's transformation into a world centre of tourism and leisure. Sands China is a subsidiary of global resort developer Las Vegas Sands Corp. (NYSE: LVS).

For more information, please visit www.sandschina.com.

Media contacts:
Corporate Communications, Sands China Ltd.
Mabel Wu
Tel: +853 8118 2268
Email: [email protected]

Jesse Chiang
Tel: +853 8118 2054
Email: [email protected]

SOURCE Sands China Ltd.

This transaction strengthens Organon’s contraception portfolio and expands long-acting reversible options for women

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced the completion of a global licensing agreement with Sebela Pharmaceuticals, granting Organon exclusive rights to MIUDELLA®, a hormone-free, copper intrauterine device (IUD). Please see our prior announcement for a summary of the transaction terms.

Approved by the US Food and Drug Administration (FDA) on February 24, 2025, MIUDELLA is the first hormone-free copper IUD to be introduced in the US in over 40 years. Indicated for the prevention of pregnancy for up to three years in females of reproductive potential, MIUDELLA is 99% effective. It features a proprietary SLIMSERTTM technology, which consists of a highly flexible frame and a fully preloaded inserter with a small, tapered insertion tube diameter of 3.7mm.1

MIUDELLA is anticipated to be commercially available in late 2026. The MIUDELLA label includes a Risk Evaluation and Mitigation Strategy (REMS). A REMS is a strategy used by the FDA to manage known or potential risks associated with a product. To mitigate complications due to potential improper insertion, MIUDELLA will only be available in the US through the MIUDELLA REMS program. See additional safety information below.

“MIUDELLA represents an important hormone-free option in contraception, expanding choices for women seeking long‑acting reversible birth control,” said Joe Morrissey, Chief Executive Officer of Organon. “By building on our long history in contraception and leveraging our deep expertise and capabilities, this agreement strengthens Organon’s ability to deliver contraceptive options that meet the needs of women.”

“Developed by Sebela Women’s Health, MIUDELLA represents an effective option for pregnancy prevention,” said Alan Cooke, Chief Executive Officer and President of Sebela Pharmaceuticals. “We are delighted to complete this global license agreement with Organon. Organon offers the scale, launch readiness and access capabilities needed to bring this valuable product efficiently into clinical practice and help ensure MIUDELLA reaches more women who are looking for hormone-free contraception options.”

Truist Securities, Inc. acted as financial advisor to Sebela Pharmaceuticals.

About MIUDELLA

MIUDELLA was investigated in three clinical trials in the US in 1,904 women aged 17 to 45 years. The Phase 3 prospective, multicenter, single-arm, open-label study was conducted in 42 centers in the US with a primary endpoint of contraceptive efficacy through 3 years of use as assessed by the Pearl Index (defined as the number of pregnancies per 100 women over one year).1 In the efficacy cohort of women aged 17 to 35 years from the Phase 3 study (n=1397), the first-year Pearl Index was 0.94 (95% CI, 0.43-1.78) and the cumulative 3-year Pearl Index was 1.05 (95% CI, 0.66-1.60)—in other words, 99% effective, with an overall placement success rate of 98.8%. The most common adverse reactions (≥5%) observed in clinical trials were heavy menstrual bleeding, dysmenorrhea, intermenstrual bleeding, pelvic discomfort, procedural pain, pelvic pain, post-procedural hemorrhage, and dyspareunia. In the first year, 8.5% of participants across all three studies discontinued treatment due to bleeding or pain adverse events, which decreased to 3.2% by year 3. Expulsion rates ranged from 1.9% in year 1 to 0.9% in year 3.

Indication

MIUDELLA® is a copper-containing intrauterine system (IUS) indicated for prevention of pregnancy in females of reproductive potential for up to 3 years. Selected Safety Information

WARNING: RISK OF COMPLICATIONS DUE TO IMPROPER INSERTION

Improper insertion of intrauterine systems, including MIUDELLA, increases the risk of complications. Proper training prior to first use of MIUDELLA can minimize the risk of improper insertion. MIUDELLA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the MIUDELLA REMS program to ensure all healthcare providers are trained on the proper insertion of MIUDELLA prior to first use. Further information is available at miudellarems.com and 1-855-337-0772. CONTRAINDICATIONS

Use of MIUDELLA is contraindicated when 1 or more of the following conditions exist: Pregnancy or suspicion of pregnancy; congenital or acquired abnormalities of the uterus, including leiomyomas, resulting in distortion of the uterine cavity; acute pelvic inflammatory disease (PID); postpartum endometritis or postabortal endometritis in the past 3 months; known or suspected uterine or cervical malignancy; for use as postcoital contraception (emergency contraception); uterine bleeding of unknown etiology; untreated acute cervicitis or vaginitis or other lower genital tract infection; conditions associated with increased susceptibility to pelvic infections; Wilson's disease; a previously placed IUS that has not been removed; hypersensitivity to any component of MIUDELLA including to polypropylene, copper, nitinol, an alloy of nickel and titanium, or any of the trace elements present in the copper component of MIUDELLA. Persons with allergic reactions to these components may suffer an allergic reaction to this intrauterine system. Prior to placement, patients should be counseled on the materials contained in the IUS, as well as potential for allergy/hypersensitivity to these materials. WARNINGS AND PRECAUTIONS

Risk of Complications Due to Improper Insertion: Improper insertion of IUSs, including MIUDELLA, increases the risk of perforation, infection, undiagnosed abnormal bleeding, pregnancy loss (if pregnancy occurs with IUS in situ), and expulsion. Proper training prior to first use of MIUDELLA can minimize the risk of improper insertion. MIUDELLA is available only through a restricted program under a REMS. MIUDELLA REMS: MIUDELLA is only available through a restricted program under a REMS called MIUDELLA REMS Program to ensure healthcare providers are trained prior to first use. Notable requirements include the following: Healthcare providers must be certified with the program by enrolling and completing training on the proper insertion of MIUDELLA prior to first use. Pharmacies and healthcare settings that dispense MIUDELLA must be certified by enrolling in the REMS and must only dispense MIUDELLA to certified healthcare providers. Further information is available at www.miudellarems.com and 1-855-337-0772.

Ectopic Pregnancy: Promptly evaluate females who become pregnant for ectopic pregnancy while using MIUDELLA. Ectopic pregnancy may require surgery and may result in loss of fertility. Intrauterine Pregnancy: Increased risk of spontaneous abortion, septic abortion, premature delivery, sepsis, septic shock, and death if pregnancy occurs. Remove MIUDELLA if pregnancy occurs with MIUDELLA in place and the thread ends are visible or can be retrieved from the cervical canal. Sepsis: Severe infection or sepsis, including Group A streptococcal sepsis (GAS), have been reported following insertion of other IUSs; strict aseptic technique is essential during insertion. Pelvic Infection: Promptly examine users with complaints of lower abdominal or pelvic pain, odorous discharge, unexplained bleeding, fever, genital lesions or sores after insertion of MIUDELLA. IUSs have been associated with an increased risk of PID, most likely due to organisms being introduced into the uterus during insertion. Remove MIUDELLA in cases of recurrent PID or endometritis, or if an acute pelvic infection is severe or does not respond to treatment. Subclinical PID: PID may be asymptomatic but still result in tubal damage and its sequelae.

Perforation: Partial or total perforation of the uterine wall or cervix may occur during insertions, although the perforation may not be detected until sometime later. Perforation may also occur at any time during IUS use. Perforation that results in embedment or translocation may reduce contraceptive efficacy and result in pregnancy. Risk is increased if inserted in postpartum and lactating females and may be increased if inserted in females with fixed, retroverted uteri or noninvoluted uteri. If perforation is suspected or if known perforation occurs during placement, the IUS should be removed as soon as possible. Surgery may be required. Delayed detection or removal of MIUDELLA in cases of perforation may result in migration outside the uterine cavity, adhesions, peritonitis, intestinal penetration, intestinal obstruction, abscesses and/or damage to adjacent organs. Expulsion: Partial or complete expulsion of MIUDELLA has been reported, resulting in the loss of contraceptive protection. MIUDELLA should be placed no earlier than 4 weeks post-pregnancy to mitigate the risk of expulsion that may be increased when the uterus is not completely involuted at the time of insertion. Remove a partially expelled MIUDELLA and do not attempt to push a partially expelled MIUDELLA into the uterus. Wilson’s Disease: MIUDELLA may exacerbate Wilson’s disease, a rare genetic disease affecting copper excretion; therefore, the use of MIUDELLA is contraindicated in females with Wilson’s disease. Bleeding Pattern Alterations: Menstrual bleeding may be altered and result in heavier and longer bleeding with spotting. Females complaining of heavy vaginal bleeding should be evaluated and treated, and may need to discontinue MIUDELLA. Magnetic Resonance Imaging (MRI) Safety Information: Patients using MIUDELLA can be safely scanned with MRI only under certain conditions. Medical Diathermy: Medical equipment that contains high levels of Radiofrequency (RF) energy such as diathermy may cause health effects (by heating tissue) in females with a metal-containing IUS including MIUDELLA. Avoid using high medical RF transmitter devices in females with MIUDELLA. ADVERSE REACTIONS

Most common adverse reactions (≥5%) observed in clinical trials were heavy menstrual bleeding, dysmenorrhea, intermenstrual bleeding, pelvic discomfort, procedural pain, pelvic pain, post-procedural hemorrhage, and dyspareunia. Before prescribing MIUDELLA, please read the full Prescribing Information, including Boxed Warning.

About Organon
Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women’s Health and General Medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 markets.

Headquartered in Jersey City, New Jersey, Organon is committed to advancing access, affordability, and innovation in healthcare. Learn more at www.organon.com and follow us on LinkedIn, Instagram, X, YouTube, TikTok and Facebook.

Cautionary Note Regarding Forward-Looking Statements
Except for historical information, this press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about the potential benefits of Organon’s exclusive license of global rights to MIUDELLA® and expectations regarding the timing of commercialization thereof. Forward-looking statements may be identified by words such as “anticipated, “may”, “will”, and “expected,” among others. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate, or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include, but are not limited to, weakening of economic conditions that could adversely affect the level of demand for MIUDELLA®; pricing pressures globally, including rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to or affecting Medicare, Medicaid and healthcare reform, pharmaceutical pricing and reimbursement, access to the company’s products, international reference pricing, including most-favored-nation drug pricing, and other pricing related initiatives and policy efforts; the impact of tariffs and other trade restrictions or domestic sourcing requirements; expanded brand and class competition in the markets in which the company operates; the failure of any supplier to provide substances, materials, or services as agreed, or otherwise meet their obligations to the company; the increased cost of supply, manufacturing, packaging, and operations; difficulties developing and sustaining relationships with commercial counterparties, including Sebela Pharmaceuticals; the impact of higher selling and promotional costs; efficacy, safety or other quality concerns with respect to the company’s marketed products, whether or not scientifically justified, leading to product recalls, withdrawals, labeling changes or declining sales; future actions of third parties, including significant changes in customer relationships or changes in the behavior and spending patterns of purchasers of healthcare products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and forgoing healthcare insurance coverage; the failure by the company or its third party collaborators and/or their suppliers to fulfill their or their regulatory or quality obligations; and volatility of commodity prices, fuel, and shipping rates that impact the costs and/or ability to supply the company’s products. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the SEC, including the company’s most recent Annual Report on Form 10-K and subsequent SEC filings, available at the SEC’s Internet site (www.sec.gov). References and links to websites have been provided for convenience, and the information contained on any such website is not a part of, or incorporated by reference into, this press release. Organon is not responsible for the contents of third-party websites.

About Sebela Pharmaceuticals
At Sebela Pharmaceuticals, we are building a leading gastroenterology company in the US and developing innovative products in women’s health. Braintree Laboratories, Inc., a part of Sebela Pharmaceuticals, has been innovating, developing, manufacturing, and commercializing gastroenterology products for over 40 years. Tegoprazan is Braintree’s lead program in GERD, and in 2025 Sebela Women’s Health obtained FDA approval for Miudella (copper-containing intrauterine system), the first non‑hormonal intra‑uterine device (IUD) for contraception approved in over 40 years. Sebela Pharmaceuticals has operations in Roswell, GA; Braintree, MA; and Dublin, Ireland.

For more information, visit www.sebelapharma.com.

Sebela Forward-Looking Statement
This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sebela Pharmaceuticals, Sebela Women’s Health and Braintree Laboratories under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These statements may be identified by the use of forward-looking words such as "anticipate," "planned," "believe," “may”, “will”, "forecast," "estimated," "expected," and "intend," among others. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the development, launch, introduction and commercial potential of Miudella; growth and opportunity, including peak sales and the potential demand for Miudella, as well as its potential impact on applicable markets; market size; substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third-party payer reimbursement; dependence upon third parties; our financial performance and results, including the risk that we are unable to manage our operating expenses or cash use for operations, or are unable to commercialize our products, within the guided ranges or otherwise as expected; and risks related to noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development and commercialization of new products. There are no guarantees that Miudella will prove to be commercially successful. While the list of factors presented here is considered representative, no such list should be considered a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and neither Sebela Pharmaceuticals, Sebela Women’s Health nor Braintree Laboratories agree to undertake any obligation to update publicly such statements to reflect subsequent events or circumstances except as required by law.

More News From Organon & Co.

The launch expands Organon’s biosimilars portfolio in Canada to eight products spanning five therapeutic areas

KIRKLAND, Quebec & SHANGHAI--(BUSINESS WIRE)--Organon Canada and Shanghai Henlius Biotech, Inc. (2696.HK) today announced that BILDYOS® (denosumab injection) 60 mg/1 mL and TUZEMTY® (denosumab injection) 120 mg/1.7 mL, biosimilars to PROLIA and XGEVA, respectively, are now available in Canada for all indications of reference products. Used across several indications, denosumab products treat osteoporosis and bone events associated with cancer by helping to strengthen bones.

“The approvals represent an important step toward helping broaden access to bone-care treatments in Canada. These biosimilars will introduce additional treatment options across several therapeutic areas, including osteoporosis, which predominantly affects women and impacts 2.3 million Canadians,”1 said Dominic Bégin, President and Managing Director at Organon Canada. “This development reinforces Organon’s commitment to expanding its biosimilar portfolio, improving treatment accessibility, and helping to strengthen the healthcare system while supporting patients in need.”

With this launch, Organon reinforces its commitment to offering patients in Canada more treatment options and helping to reduce healthcare costs by increasing access to biosimilars. BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection) have joined Organon’s growing biosimilars portfolio in Canada, which spans five therapeutic areas, including oncology, and includes products with more than nine years of market experience.

“The availability of BILDYOS® and TUZEMTY® marks an important step in our collaboration with Organon,” said Darius Panaligan, Chief Commercial Officer, International Markets of Henlius. “Together, we’ve translated our shared vision into tangible outcomes, helping to bring new treatment options to patients in Canada and reinforcing our joint commitment to long-term access.”

These product launches reflect Organon’s long-standing commitment to expanding access to cost-effective treatments and advancing women’s health through a patient-centered approach.

“The addition of new approved denosumab therapies help reinforce a resilient healthcare system and supports clinicians and patients in navigating osteoporosis treatment options with greater flexibility,” said Dr. Famida Jiwa, President and CEO, Osteoporosis Canada.

In 2022, Henlius entered into a license and supply agreement with Organon, granting Organon the exclusive commercialization rights to several biosimilars, including BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection). The agreement covers exclusive global commercialization rights except for China.

For more information about these products, including important safety information, visit: BILDYOS_PM-E.pdf and TUZEMTY_PM-E.pdf

About Organon
Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women’s Health, Biosimilars and General Medicines, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 markets. For more information, visit https://www.organon.com/canada-en/ and connect with us on LinkedIn.

About Henlius
Shanghai Henlius Biotech, Inc. (2696.HK) is a global, innovation-driven biopharmaceutical company committed to delivering high-quality, affordable biologic therapies to patients worldwide. The Company focuses on major disease areas including oncology, autoimmune diseases, and ophthalmic diseases. Founded in 2010, Henlius has established an integrated, end-to-end biopharmaceutical platform encompassing global R&D, clinical operations, regulatory affairs, manufacturing, and commercialisation. The Company employs nearly 4,000 people globally and operates across multiple regions, including China, the United States, and Japan. Leveraging the stable cash flow generated from its biosimilar portfolio to support innovation, Henlius is steadily advancing into its “Globalisation 2.0” phase, building a scalable and sustainable global growth model. As of early 2026, Henlius has achieved regulatory approvals for 10 products across over 60 countries and regions worldwide, including eight approvals in China. The Company has also reached multiple milestones in major biopharmaceutical markets, with four products approved by the U.S. Food and Drug Administration (FDA) and five products approved by the European Commission (EC), reflecting its globally aligned R&D capabilities, quality systems, and manufacturing standards.

Driven by innovation, Henlius has built a diversified, platform-based technology ecosystem through coordinated R&D efforts across Shanghai, the United States, and other regions. Its innovation platforms span immune checkpoint inhibitors, immune cell engager technologies (including multispecific T cell engagers), antibody-drug conjugates (ADCs), and AI-enabled early discovery platforms. The Company currently has more than 50 early-stage innovative assets, approximately 70% of which are expected to be best-in-class, with over 30 clinical trials ongoing globally. Henlius’ core product, serplulimab (trade name: Hetronifly® in Europe), is the world’s first anti–PD-1 mAb approved for first-line treatment of small cell lung cancer and has been approved in 50 markets worldwide with an accelerated globalisation process. In parallel, multiple high-potential innovative assets—including the PD-L1 ADC HLX43 and the novel epitope anti-HER2 mAb HLX22—are advancing through global pivotal clinical development. Supported by a biologics manufacturing network with a total capacity of 84,000L and GMP certifications from regulatory authorities in China, Europe, and the United States, Henlius has established a stable global supply system serving six continents. Guided by a patient-centred mission, Henlius remains focused on addressing unmet medical needs and translating scientific innovation into meaningful clinical value and patient access, contributing sustainably to the global biopharmaceutical ecosystem.

To learn more about Henlius, visit https://www.henlius.com/en/index.html and connect with us on LinkedIn at https://www.linkedin.com/company/henlius/.

1 What is osteoporosis? Osteoporosis Canada. 2024. Accessed April 27, 2026. https://osteoporosis.ca/what-is-osteoporosis/

More News From Organon & Co.

Key Takeaways Iron Mountain's recurring storage revenues and pricing supported strong first-quarter 2026 growth. IRM's data center revenues jumped 47.1% as leasing stayed strong and utilization remained high.IRM grew digital and asset lifecycle businesses over 50% year over year, boosting service revenues. Iron Mountain Incorporated (IRM - Free Report) shares have rallied 30.2% in the past three months compared with the industry’s growth of 10.2%.

Iron Mountain’s recurring storage rental revenues remain resilient through pricing and strong retention, while rapid data center expansion, robust leasing demand, and growing digital and asset lifecycle management businesses continue to drive growth and diversify revenues beyond traditional records storage.

Analysts seem bullish on this Zacks Rank #3 (Hold) stock. The Zacks Consensus Estimate for its 2026 AFFO per share has been revised northward by 13 cents to $5.85 over the past two months.

Image Source: Zacks Investment Research

Factors Behind IRM Stock’s Price SurgeIron Mountain continues to rely on highly recurring storage rental revenues, supported by pricing, revenue management and strong customer retention. In the first quarter of 2026, consolidated storage rental revenues increased 15.4% year over year, while Global RIM storage rental grew 8.7%. These results indicate that pricing and revenue management continue to help offset gradual declines in physical storage volumes. Management also highlighted that the physical records storage business delivered its best quarterly growth in years, helping fund investment in faster-growing offerings.

The Global Data Center business remains Iron Mountain's primary growth engine, benefiting from sustained enterprise and hyperscale demand for secure, interconnected capacity. In the first quarter of 2026, data center revenues increased 47.1% year over year to $254.7 million, driven primarily by 46% increase in storage rental revenues, while adjusted EBITDA margin remained above 50% at 52.1%. The operating portfolio reached 507.2 megawatt (MW) from 424.2 MW a year ago and was 97.2% leased, reflecting strong utilization. Leasing activity remained healthy, with 21,849 kilowatt (KW) of new and expansion leases signed during the quarter.

Management reported 32 MW of data center leasing from the beginning of the year through April 2026, suggesting demand carried into the early second quarter. Churn remained low at 0.4%, while cash mark-to-market was 12%, pointing to pricing power on renewals. The development pipeline also expanded, with 181.5 MW under construction and 684.2 MW held for future development, bringing total potential data center capacity to 1.37 gigawatt (GW). This robust pipeline supports the company’s strategy to build and energize capacity ahead of demand and sustain high growth rates as more sites come online.

Iron Mountain is broadening beyond traditional records storage through digital and asset lifecycle management capabilities that management is increasingly cross-selling across its large customer base. Management said that the data center, digital and ALM businesses grew more than 50% year over year in first-quarter 2026, while consolidated service revenues rose 30.6% year over year to $841 million.

Within Global RIM, service revenues increased 16.5% year over year, indicating healthy demand for higher-value services alongside storage. Recent acquisitions in IT asset disposition and logistics capabilities extend the lifecycle offering set and deepen customer relationships, which can improve wallet share over time, even as paper-based workflows evolve. The company’s global footprint and broad customer mix also help scale these newer offerings across regions and industries.

Key Concerns for Iron MountainCompetition from other industry players is likely to lead to aggressive pricing pressure and hurt Iron Mountain’s prospects. High interest expenses and adverse foreign currency movements remain a concern.

Stocks to ConsiderSome better-ranked stocks from the broader REIT sector are Lamar Advertising (LAMR - Free Report) and Vornado Realty Trust (VNO - Free Report) , each carrying a Zacks Rank of 2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Zacks Consensus Estimate for LAMR’s 2026 FFO per share is pegged at $8.81, which indicates year-over-year growth of 6.66%.

The Zacks Consensus Estimate for VNO’s full-year FFO per share is pinned at $2.34, which calls for an increase of 0.86% from the year-ago period.

Note: Anything related to earnings presented in this write-up represents FFO, a widely used metric to gauge the performance of REITs.

-

MILWAUKEE--(BUSINESS WIRE)--Zurn Elkay Water Solutions Corporation (NYSE: ZWS) has been named one of America’s High-Growth Companies 2026 for the first time by Business Insider and Plant-A Insights Group. Among the 500 companies on the list, Zurn Elkay is one of only 50 manufacturers and one of only six Wisconsin-based companies.

“With clean, safe water at the heart of our business, our growth strategy and our sustainability strategy are increasingly the same,” said Todd A. Adams, Chairman and CEO of Zurn Elkay Water Solutions.

Share “With clean, safe water at the heart of our business, our growth strategy and our sustainability strategy are increasingly the same,” said Todd A. Adams, Chairman and CEO of Zurn Elkay Water Solutions. “The world is facing escalating water conservation and contamination issues, and we’ve built a core business uniquely positioned to meet those challenges with solutions that make water safe and more sustainable. Whether it’s drinking water filtration that reduces forever chemicals and other emerging contaminants or backflow preventers that stop contaminated water from entering the potable water system, each new innovation reflects our unwavering commitment to protecting the world’s most vital resource while creating lasting value for our customers and shareholders.”

Business Insider's America's High-Growth Companies 2026 is based on an extensive assessment of financial records against 11 financial growth metrics for over 3,000 US publicly listed companies on the New York Stock Exchange (NYSE) and Nasdaq. Companies were evaluated on their ability to maintain high-quality growth, and eligibility was restricted to companies that have been public since 2020 and achieved both a minimum revenue of $100 million and profitability in fiscal year 2025.

Zurn Elkay’s financial performance has also been recognized by TIME in its lists of America’s Growth Leaders (2025-2026) and World’s Best Companies for Sustainable Growth (2025-2026). The company has earned recognition from Newsweek in its list of America’s Most Responsible Companies (2021-2026), the World’s Greenest Companies (2026) and America’s Greenest Companies (2025-2026), as well as Barron’s 100 Most Sustainable Companies (2026).

To learn more about Zurn Elkay Water Solutions and its sustainability efforts, including the company’s most recent sustainability report, visit zurnelkay.com/sustainability.

About Zurn Elkay Water Solutions

Named one of the World’s Greenest Companies and one of America’s Most Responsible Companies by Newsweek and one of the World’s Best Companies for Sustainable Growth by TIME, Zurn Elkay Water Solutions is headquartered in Milwaukee, Wisconsin, and is a growth-oriented, pure-play water management business that designs, procures, manufactures and markets what we believe to be the broadest sustainable product portfolio of specification-driven water management solutions to improve health, hydration, human safety and the environment. The Zurn Elkay product portfolio includes professional grade water safety and control products, flow systems products, hygienic and environmental products and filtered drinking water products for public and private spaces. Learn more at zurnelkay.com.

Cautionary Statement on Forward-Looking Statements

Information in this release may involve outlook, expectations, beliefs, plans, intentions, strategies or other statements regarding the future, which are forward-looking statements. These forward-looking statements involve risks and uncertainties. All forward-looking statements included in this release are based on information available to Zurn Elkay Water Solutions as of the date of this release, and Zurn Elkay Water Solutions assumes no obligation to update any such forward-looking statements. The statements in this release are not guarantees of future performance, and actual results could differ materially from current expectations. Numerous factors could cause or contribute to such differences. Please refer to “Risk Factors” and “Cautionary Notice Regarding Forward-Looking Statements” in our report on Form 10-K for the period ended December 31, 2025, as well as the Company’s subsequent annual, quarterly and current reports filed on Forms 10-K, 10-Q and 8-K from time to time with the Securities and Exchange Commission for a further discussion of the factors and risks associated with the business.

More News From Zurn Elkay Water Solutions Corporation

Back to Newsroom

NEW YORK, June 21, 2026 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Manhattan Associates, Inc. (NASDAQ: MANH).

If you currently own shares of Manhattan Associates stock, please visit the firm’s website at https://rosenlegal.com/submit-form/?case_id=35966 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected].

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:        

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

, /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Manhattan Associates, Inc. (NASDAQ: MANH).

If you currently own shares of Manhattan Associates stock, please visit the firm's website at https://rosenlegal.com/submit-form/?case_id=35966 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected].

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions.  Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:                         

     Laurence Rosen, Esq.
     Phillip Kim, Esq.
     The Rosen Law Firm, P.A.
     275 Madison Avenue, 40th Floor
     New York, NY  10016
     Tel: (212) 686-1060
     Toll Free: (866) 767-3653
     Fax: (212) 202-3827
     [email protected]
      www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

NEW YORK, June 21, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GoDaddy Inc. (NYSE: GDDY) resulting from allegations that GoDaddy may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased GoDaddy securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/cases/godaddy-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

WHAT IS THIS ABOUT: Rosen Law Firm is investigating potential civil securities claims.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.

Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.

The Style Scores are broken down into four categories:

Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.

Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.

Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.

VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +24% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.

That's where the Style Scores come in.

To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.

The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.

A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: GoDaddy (GDDY - Free Report) GoDaddy’s solutions serve roughly 20 million customers that include independents, WebPros, Domain Registrars and Investors, and Third-Party Registrars and Corporate Domain Portfolio owners.

GDDY is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.

It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 10.51; value investors should take notice.

Four analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.08 to $7.14 per share. GDDY also boasts an average earnings surprise of +6.1%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, GDDY should be on investors' short list.

-

PITTSBURGH--(BUSINESS WIRE)--Wabtec Corporation (NYSE: WAB) announced it will report 2026 second quarter results before the U.S. financial markets open on July 22, 2026. The company will conduct a conference call to discuss those results with analysts and investors at 8:30 a.m. ET the same day. To listen to the call via webcast, visit Wabtec’s website at www.WabtecCorp.com and click on “Events & Presentations” in the “Investor Relations” section. An audio replay of the call will be available by calling 1-855-669-9658 or 1-412-317-0088 (access code: 2758919).

About Wabtec Corporation

Wabtec Corporation is revolutionizing the way the world moves for future generations. The Company is a leading global provider of equipment, systems, digital solutions and value-added services for the freight and transit rail industries, as well as the mining, marine and industrial markets. Wabtec has been a leader in the rail industry for over 155 years and has a vision to achieve a sustainable rail system in the U.S. and worldwide. Visit Wabtec’s website at www.wabteccorp.com.

More News From Wabtec Corporation

Back to Newsroom

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

To view the full publication, “Next-Generation DNA Repair Therapies Open New Frontiers in Oncology,”  please visit: https://ibn.fm/LL2Es

Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors (“DDRi”), which work by blocking cancer cells’ ability to repair their own damaged DNA, is expanding rapidly beyond its original anchor, the PARP inhibitor. DDRi therapies collectively represented an estimated $7-plus billion in global sales in 2025, and the broader oncology, diagnostics and precision medicine markets are projected to climb to roughly $750 billion by 2030.

New inhibitor classes are emerging as the next major wave. Sitting at the forefront of this shift is Onco-Innovations Limited, a Canadian clinical-stage oncology company developing ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor that targets a DNA repair enzyme involved in multiple DNA repair pathways. As the field races to find the next generation of synthetic lethality assets, Onco-Innovations occupies a unique space as it strengthens its position in the biopharmaceutical and biotechnology sector.

About Onco-Innovations Limited

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumors.

For further information, please visit the company’s website at www.OncoInnovations.com.

NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

DISCLAIMER: BioMedWire (BMW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by BMW are solely those of BMW. Readers of this Article and content agree that they cannot and will not seek to hold liable BMW for any investment decisions by their readers or subscribers. BMW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, BMW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

BMW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BMW undertakes no obligation to update such statements.

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
[email protected]

BioMedWire is powered by IBN

, /PRNewswire/ -- Cboe Global Markets, Inc. (Cboe: CBOE), a leading global markets operator and pioneer in equity and index derivatives, today announced the launch of the first products in its new prediction markets suite, Cboe PredictsSM.

The offering includes binary option contracts based on the Mini-S&P 500 Index (XSP), listed under the symbols XSPBW and XSPBX. The contracts are now available on Interactive Brokers and expected to roll out at Charles Schwab in the coming months, with additional retail brokerage platforms expected to offer access over time. 

Cboe PredictsSM represents the latest expansion of Cboe's S&P 500 Index (SPX) product suite. XSP allows customers to trade on the performance of the S&P 500 Index (SPX) but is scaled to 1/10th the size of SPX – making it a smaller, more retail-friendly alternative. Traders can express a view on where XSP may close by taking a "yes" position (paying $100 if the index settles at or above a specified level, or $0 otherwise) or a "no" position (paying $100 if it settles below that level, or $0 otherwise).

"Following the success of SPX 0DTE options, we have seen continued customer demand for shorter-dated, outcome-based trading, creating a natural extension for Cboe to introduce XSP binary options," said JJ Kinahan, Head of Retail Expansion and Alternative Investment Products at Cboe. "Cboe's S&P 500 options suite has long provided traders with flexibility to define their outcomes through traditional options strategies. With Cboe Predicts, we are expanding that choice by offering simple 'yes-or-no' payout event contracts, supported by dedicated educational resources designed to help customers participate more confidently and responsibly." 

In a future release, Cboe also plans to enable trading of XSP vertical spreads through its proprietary, patent-pending Quoted Spread BookSM (QSBSM) framework. The framework is designed to package widely used options strategies into a simpler, more intuitive format, helping newer traders already comfortable with "yes/no" outcomes build familiarity with more advanced options concepts within defined-risk strategies. 

Through access provided by leading retail brokers, Cboe's intermediated model is designed to encompass high standards for customer education, market access and oversight. Additionally, these securities-based products are centrally cleared through the Options Clearing Corporation (OCC), providing enhanced risk management during the settlement process.

"OCC stands ready to bring the same clearing infrastructure and risk management discipline that underpins all of the products we clear to the new binary options," said Mike Hansen, Chief Clearing and Settlement Services Officer at OCC. "Our commitment to operational excellence and financial integrity ensures that participants can engage with confidence, knowing every transaction is supported by sound, well-established clearing and settlement services."

"Investors increasingly seek products that allow them to express a specific view on future events and market outcomes," said Milan Galik, Chief Executive Officer of Interactive Brokers. "Cboe's binary options and Mini-S&P 500 Index contracts provide another way to do that, and we are pleased to make them available to Interactive Brokers clients."

"We support approaches that bring transparency, defined risk, and investor education to financial-related prediction markets," said James Kostulias, Head of Trading Services, Charles Schwab. "We plan to offer clients access to these binary options contracts in the coming months, building on our existing platform and demand from active traders."

"For more than 50 years, Cboe has built and operated some of the world's most established and trusted markets," said Rob Hocking, Global Head of Derivatives at Cboe. "We look forward to bringing our experience, trusted market infrastructure and the deep liquidity of the SPX options ecosystem to prediction markets. Our goal is to help set a higher standard for market integrity, product design and investor protection by offering access through a regulated securities exchange and central clearing through OCC."

Cboe has also introduced educational resources, including a new prediction markets resource hub and courses through The Options Institute, a leader in options education for more than 40 years. These courses guide learners from market basics and decision-making through Cboe's 'yes/no' contracts, then into core options concepts.

Cboe's XSP prediction market contracts are security options and will trade within the same regulatory framework as U.S.-listed options, providing institutional-grade liquidity, transparency, and surveillance, among other benefits.

About Cboe Global Markets

Cboe Global Markets (Cboe: CBOE) is a leading global markets operator with a long history of innovation in equity and index derivatives. Since launching the world's first listed options exchange in 1973, Cboe has pioneered landmark products, including the introduction of S&P 500® index options and the creation of the VIX® Index, the world's leading gauge of market volatility, reshaping how investors manage risk and access opportunity. Today, Cboe operates derivatives, equities, and FX markets, providing trading, clearing, and investment solutions for customers worldwide. To learn more, visit www.cboe.com.

Cboe Media Contacts

‌      

Cboe Analyst Contact

Angela Tu

‌     

Tim Cave

Kenneth Hill, CFA

+1-646-856-8734

+44 (0) 7593-506-719

+1-312-786-7559

[email protected]

[email protected]

[email protected]

CBOE-C
CBOE-OE

Cboe®, Cboe Global Markets®, and VIX ® are registered trademarks and Cboe PredictsSM, Quoted Spread BookSM, and QSBSM are service marks of Cboe Exchange, Inc., and S&P 500® is a registered trademark of Standard & Poor's Financial Services LLC. All other trademarks and service marks are the property of their respective owners. 

Cautionary Statements Regarding Forward-Looking Information

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. You can identify these statements by forward-looking words such as "may," "might," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," and the negative of these terms and other comparable terminology. All statements that reflect our expectations, assumptions or projections about the future other than statements of historical fact are forward-looking statements. These forward-looking statements, which are subject to known and unknown risks, uncertainties and assumptions about us, may include projections of our future financial performance based on our growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from those expressed or implied by the forward-looking statements.

We operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible to predict all risks and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

Some factors that could cause actual results to differ include: the loss of our right to exclusively list and trade certain index options and futures products; economic, political and market conditions; compliance with legal and regulatory obligations; price and new products and services competition and consolidation in our industry; decreases in trading or clearing volumes, market data fees or a shift in the mix of products traded on our exchanges; legislative or regulatory changes or changes in tax regimes; our ability to protect our systems and communication networks from security vulnerabilities and breaches; our ability to attract and retain skilled management and other personnel; increasing competition by foreign and domestic entities; our business and operational dependence on and exposure to risk from third parties; factors that impact the quality and integrity of our and other applicable indices; our ability to manage our global operations, growth, and strategic acquisitions, wind downs, divestitures, or alliances effectively; increases in the cost of the products and services we use; our ability to operate our business without violating the intellectual property rights of others and the costs associated with protecting our intellectual property rights; our ability to minimize the risks, including our credit, liquidity, market, investment, counterparty, and default risks, associated with operating our clearinghouses; our ability to accommodate trading and clearing volume and transaction traffic, including significant increases, without failure or degradation of performance of our systems; misconduct by those who use our markets or our products or for whom we clear transactions; challenges to our use of open source software code; our ability to meet our compliance obligations, including managing our business interests and our regulatory responsibilities; the loss of key customers or a significant reduction in trading or clearing volumes by key customers; damage to our reputation; the ability of our compliance and risk management methods to effectively monitor and manage our risks; restrictions imposed by our debt obligations and our ability to make payments on or refinance our debt obligations; our ability to maintain an investment grade credit rating; impairment of our goodwill, long-lived assets, investments or intangible assets; the accuracy of our estimates and expectations; and litigation risks and other liabilities. More detailed information about factors that may affect our actual results to differ may be found in our filings with the SEC, including in our Annual Report on Form 10-K for the year ended December 31, 2025 and other filings made from time to time with the SEC.

We do not undertake, and we expressly disclaim, any duty to update any forward-looking statement whether as a result of new information, future events or otherwise, except as required by law. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

SOURCE Cboe Global Markets, Inc.

Achieving the rigorous laboratory standard broadens access for providers and patients in New York; applies to use of Haystack MRD for patients with solid tumor cancers

, /PRNewswire/ -- Quest Diagnostics® (NYSE: DGX), a leading provider of diagnostic information services, today announced that the New York State Department of Health's (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) has approved the company's Haystack MRD® test, a circulating tumor DNA (ctDNA) liquid biopsy test, for use in identifying residual or recurring disease in patients with a range of solid tumor cancers.

New York maintains a highly rigorous clinical laboratory oversight program, requiring formal technical review and approval of laboratory developed tests before they may be offered to patients in the state. With this approval, Haystack MRD is now authorized for patient testing in all 50 U.S. states. The test was developed under CLIA regulations and has been available for clinician ordering since late 2024 in 49 states and the District of Columbia.

"This approval represents the culmination of our many years of hard work and commitment to delivering a highly accurate test that can meaningfully improve patient care," said Dan Edelstein, Vice President and General Manager for Haystack Oncology, a Quest Diagnostics company. "Haystack MRD was designed to give oncologists the confidence to detect residual disease earlier, catch recurrence before it becomes clinically apparent, and help identify response to treatment. New York's approval is another proof point for Haystack MRD's quality and technical sophistication, and we look forward to extending access to this important innovation for clinicians and patients in the state."

In addition, Haystack MRD's clinical utility has been demonstrated in rigorous investigational settings, including the landmark study of non-operative management of patients with locally advanced mismatch repair–deficient (dMMR) solid tumors, which was led by Dr. Andrea Cercek and colleagues at Memorial Sloan Kettering Cancer Center and published in The New England Journal of Medicine in May 2025. In that study, ctDNA testing, using Haystack MRD, was found to be a "reliable liquid biopsy surrogate" that identified clinical complete response at a median of 1.4 months, compared to more than 6 months using imaging methods.

"In our study of non-operative management for dMMR solid tumors, the use of MRD testing provided additional molecular information that complemented traditional assessments such as imaging and endoscopy," said Dr. Cercek, Medical Oncologist, Memorial Sloan Kettering Cancer Center. "For patients who may avoid surgery, having multiple tools to evaluate treatment response and monitor for recurrence is important. These findings highlight the crucial role of MRD testing in informing patient management and underscore the need for continued study as these approaches are integrated into clinical practice."

About Haystack Oncology
Haystack Oncology represents the culmination of over 20 years of collaboration to advance technical and clinical development in liquid biopsy technologies by cancer genomics pioneers at Johns Hopkins School of Medicine. The company, a wholly owned subsidiary of Quest Diagnostics, developed Haystack MRD, a tumor-informed, next-generation MRD test that detects ultralow levels of ctDNA to uncover residual or recurrent disease with exceptional sensitivity and specificity. Haystack Oncology works with biopharmaceutical companies to accelerate and inform clinical development programs and advance important therapeutics to global markets, from early phase clinical development to companion diagnostics. Haystack MRD was developed and validated in a CLIA-certified laboratory and is available for commercial use as a lab-developed test (LDT) by Quest Diagnostics. The FDA granted Haystack MRD Breakthrough Device Designation in 2025 for use in Stage II colorectal cancer. Haystack MRD is also available for clinical trials as an investigational device by Haystack Oncology in laboratories located in Baltimore, Maryland; Hamburg, Germany; and Helsinki, Finland. www.haystackmrd.com

About Quest Diagnostics
Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenues to identify and treat disease, empower healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three American adults each year, and our nearly 57,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com

SOURCE Quest Diagnostics

In the latest trading session, SharkNinja, Inc. (SN - Free Report) closed at $138.56, marking a -1.62% move from the previous day. This move lagged the S&P 500's daily loss of 0.37%. Elsewhere, the Dow gained 0.29%, while the tech-heavy Nasdaq lost 1.33%.

The company's stock has climbed by 25.72% in the past month, exceeding the Consumer Discretionary sector's gain of 1.15% and the S&P 500's gain of 2.02%.

Analysts and investors alike will be keeping a close eye on the performance of SharkNinja, Inc. in its upcoming earnings disclosure. In that report, analysts expect SharkNinja, Inc. to post earnings of $1.1 per share. This would mark year-over-year growth of 13.4%. At the same time, our most recent consensus estimate is projecting a revenue of $1.64 billion, reflecting a 13.66% rise from the equivalent quarter last year.

For the full year, the Zacks Consensus Estimates project earnings of $6.12 per share and a revenue of $7.19 billion, demonstrating changes of +15.91% and +12.35%, respectively, from the preceding year.

Investors should also pay attention to any latest changes in analyst estimates for SharkNinja, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been a 0.09% rise in the Zacks Consensus EPS estimate. SharkNinja, Inc. presently features a Zacks Rank of #3 (Hold).

Digging into valuation, SharkNinja, Inc. currently has a Forward P/E ratio of 23.02. This signifies a premium in comparison to the average Forward P/E of 15.34 for its industry.

We can additionally observe that SN currently boasts a PEG ratio of 1.77. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Consumer Products - Discretionary was holding an average PEG ratio of 1.13 at yesterday's closing price.

The Consumer Products - Discretionary industry is part of the Consumer Discretionary sector. Currently, this industry holds a Zacks Industry Rank of 80, positioning it in the top 33% of all 250+ industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.

-

ST. LOUIS--(BUSINESS WIRE)--Reinsurance Group of America, Incorporated (NYSE: RGA), a leading global life and health reinsurer, announced today that Laura Cockrill has been named Chief Financial Officer, effective immediately. She succeeds Axel André, who will leave the company on July 17 to pursue a new opportunity. Most recently, Ms. Cockrill served as Chief Strategy Officer and as a member of RGA’s Executive Committee.

“During her more than 25 years with RGA, Laura has excelled in positions of increasing responsibility across the finance organization and the company more broadly,” said Tony Cheng, President and Chief Executive Officer, RGA. “She has played a pivotal role in shaping and advancing our enterprise strategy and long-term growth priorities. Laura is a proven leader who brings an unmatched understanding of our business, and I look forward to continuing to work closely with her to achieve our financial objectives and create long-term value for our shareholders. I would also like to thank Axel for his numerous contributions during his tenure and wish him all the best as he embarks on this exciting new chapter.”

Prior to her current role, Ms. Cockrill served as the organization’s Deputy Chief Financial Officer, and before that, as Chief Financial Officer for the Americas region. During her career with the company, she has held a wide range of finance roles, giving her deep expertise across business, capital, collateral, investments, treasury, and financial planning and analysis. She will remain a member of RGA’s Executive Committee.

About RGA

Reinsurance Group of America, Incorporated (NYSE: RGA) is a global industry leader specializing in life and health reinsurance and financial solutions that help clients effectively manage risk and optimize capital. Founded in 1973, RGA is one of the world’s largest and most respected reinsurers and remains guided by a powerful purpose: to make financial protection accessible to all. As a global capabilities and solutions leader, RGA empowers partners through bold innovation, relentless execution, and dedicated client focus, all directed toward creating sustainable long-term value. RGA has approximately $4.3 trillion of life reinsurance in force and total assets of $164.1 billion as of March 31, 2026. To learn more about RGA and its businesses, please visit rgare.com or follow RGA on LinkedIn and Facebook. Investors can learn more at investor.rgare.com.

More News From Reinsurance Group of America, Incorporated

Back to Newsroom

Arm (ARM 1.71%) is benefiting from AI, efficiency, and licensing growth across multiple platforms, while Intel (INTC +2.27%) seeks a strategic comeback through Data Center expansion and foundry services. This video analyzes the key catalysts, market debate, and which stock may have the stronger long-term prospects.

Stock prices used were the market prices of June 11, 2026. The video was published on June 20, 2026.

Rick Orford has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Arm Holdings and Intel. The Motley Fool has a disclosure policy. Rick Orford is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link, they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.

Shares of Arm Holdings (NASDAQ:ARM | ARM Price Prediction) stock are down 10% today, trading near $367 in Tuesday afternoon action. The slide pulls Arm shares well below their June 17 all-time intraday high of $444.8 and lands inside a broad, Korean-led chip and AI selloff rather than any Arm-specific stumble.

Even after today’s drop, Arm stock remains up 235% in 2026, one of the most extreme runs in the semiconductor space this year. That backdrop is exactly why traders are now asking whether this pullback is a routine pause or a more meaningful take-profits signal.

The setup is unusually loaded. A Street-high analyst target sits alongside a triple-digit price-to-earnings multiple, leaving Arm Holdings caught between a powerful agentic AI growth story and one of the most stretched valuations in large-cap tech.

Broad Chip Selloff Pressures Arm Holdings Tuesday’s move reads as sector pain rather than company-specific news. Asian tech rolled over hard overnight, with South Korea’s KOSPI down 10%, and that risk-off wave carried into U.S.-listed AI and semiconductor names by the open.

Arm stock had also climbed sharply into the move, which left little cushion. Monday’s close sat at $407.72, leaving Arm shares stretched into Tuesday’s reversal.

That combination of sector-wide de-risking and a vertical chart is a textbook recipe for an outsized single-day drawdown in a high-beta name. Arm Holdings carries a beta of 3.79, which amplifies sector moves in both directions and helps explain the magnitude of today’s slide.

The Bull Case: Bernstein’s $500 Street-High Target An aggressive bull voice belongs to Bernstein, which recently raised its Arm stock price target from $300 to an eyebrow-raising $500, an increase of nearly 70%, while maintaining an Outperform rating. The firm’s thesis rests on Arm’s positioning in agentic AI, where power-efficient architectures matter more than ever.

Bernstein highlights the Arm AGI CPU, launched last quarter, delivering more than 2x performance per rack versus x86-based platforms. The analyst team also expects Arm to reach its $15 billion own-chip sales target earlier than anticipated on stronger-than-expected demand.

The fundamentals back the optimism. For fiscal Q4 2026, Arm posted record revenue of $1.49 billion, up 20% year over year, with licensing revenue up 29% to $819 million and data center royalties more than doubling year over year.

The Bear Case: Valuation and a Target Below the Tape The cautious side of the ledger starts with the multiple. Arm stock trades at a trailing P/E ratio of about 431x, and a forward non-GAAP P/E ratio of about 202x versus an industry average near 24x.

The analyst community is also notably split. While Bernstein and Mizuho both sit at $500 with Outperform ratings, Wells Fargo is at $410, Barclays at $360, and Bank of America at $335. The consensus average target sits near $282.93, well below where Arm shares trade today.

That tension is the heart of the take-profits question. A 235% year-to-date run, an extreme earnings multiple, and a stock trading above the average Wall Street target are exactly the conditions under which a broad sector selloff can morph into a deeper unwind.

What Investors Can Watch From Here The Arm story hasn’t changed in a single session. Agentic AI demand, AGI CPU traction, and hyperscaler design wins remain intact, and Tuesday’s slide looks more like a sector reset than a fundamental break in the thesis.

However, the math is harder to ignore at these levels. With Arm Holdings shares above the consensus target and a triple-digit P/E ratio, investors can watch for whether broader chip sentiment stabilizes through the close and whether Arm stock holds support near recent breakout levels rather than retracing more of the 2026 advance.

Whether today’s drawdown is a buying opportunity or a take-profits signal is a genuinely open question for Arm stock traders. Investors with outsized gains should consider keeping their position sizes modest, while longer-term holders can weigh the agentic AI thesis against one of the richest valuations in the semiconductor sector.

Arm Holdings PLC (NASDAQ:ARM) stock is up 3% before the bell after analyst praise. UBS raised its price target to $470 from $260, while TD Cowen lifted its target to $475 from $265, both citing improving demand for central processing units (CPUs) as agentic AI adoption accelerates.

The chipmaker has been one of the market's standout performers in 2026, up 235% year to date. The shares touched a record high on June 18 of $452.70 before pulling back sharply over the last two sessions amid the broader global tech rout. 

Notably, short interest rose 14.9% over the last month and now stands at 18.51 million shares, representing 12.8% of ARM's available float. At the stock's average pace of trading, it would take nearly two days for those bearish bets to be covered.

Meanwhile, ARM carries a Schaeffer's Volatility Scorecard (SVS) of 96 out of 100, indicating the shares have consistently delivered larger moves than options traders have priced in over the past year.